NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/29/19
NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract CancerGlobeNewsWire • 10/25/19
NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare ConferenceGlobeNewsWire • 08/29/19
NuCana Reports Second Quarter 2019 Financial Results and Provides Business UpdateGlobeNewsWire • 08/21/19
NuCana stock falls 21% after company suspends patient enrollment in pancreatic cancer trialMarket Watch • 08/20/19
Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility AnalysisGlobeNewsWire • 08/20/19